We can’t show the full text here under this license. Use the link below to read it at the source.
Heart Failure with Preserved Ejection Fraction and Obstructive Sleep Apnea: A Novel Paradigm for Additional Cardiovascular Benefit of SGLT2 Inhibitors in Subjects With or Without Type 2 Diabetes
Heart Failure with Normal Pumping and Sleep Apnea: Possible Extra Heart Benefits of SGLT2 Inhibitors in People With or Without Type 2 Diabetes
AI simplified
Abstract
(SGLT2is) may have favorable effects on (HFpEF) and (OSA).
- SGLT2is could enhance heart and kidney function, particularly in patients with HFpEF.
- These medications may help redistribute body fat, reducing visceral and subcutaneous adipose tissue.
- SGLT2is are associated with increased fat breakdown and fatty acid oxidation.
- There is potential for SGLT2is to prevent the onset and progression of nonalcoholic fatty liver disease (NAFLD) in individuals with type 2 diabetes.
- The prevalence of NAFLD in patients with OSA is estimated to exceed 50%, highlighting a significant overlap between these conditions.
AI simplified
Key numbers
40–50%
Prevalence of
accounts for approximately 40–50% of incident heart failure overall.
48%
Prevalence of in Heart Failure Patients
was present in 48% of patients with heart failure.
0.77
SGLT2i Effect on Cardiovascular Events
Hazard ratio for cardiovascular death and hospitalization in patients treated with .